

Rumyana Markovska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7963642/publications.pdf>

Version: 2024-02-01

62
papers

837
citations

516710

16
h-index

552781

26
g-index

62
all docs

62
docs citations

62
times ranked

1251
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary tract infections: Should we think about the anaerobic cocci?. <i>Anaerobe</i> , 2022, 77, 102509.	2.1	13
2	Investigation of multidrug-resistant <i>Helicobacter pylori</i> in pediatric patients: A Bulgarian study and literature data. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2022, , .	0.8	4
3	Increase in amoxicillin resistance in <i>Helicobacter pylori</i> from Bulgarian patients over 15 years. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 104, 115746.	1.8	2
4	Molecular epidemiology, virulence and antimicrobial resistance of Bulgarian methicillin resistant <i>Staphylococcus aureus</i> isolates. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2022, 69, 193-200.	0.8	4
5	Detection of different colistin resistance mechanisms among multidrug resistant <i>Klebsiella pneumoniae</i> isolates in Bulgaria. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2022, , .	0.8	2
6	Fecal Carriage and Epidemiology of Extended-Spectrum Beta-Lactamase/Carbapenemases Producing Enterobacterales Isolates in Bulgarian Hospitals. <i>Antibiotics</i> , 2021, 10, 747.	3.7	6
7	<i>Gardnerella vaginalis</i> in urinary tract infections, are men spared?. <i>Anaerobe</i> , 2021, 72, 102438.	2.1	5
8	Delafloxacin against <i>Helicobacter pylori</i> , a potential option for improving eradication success?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114980.	1.8	4
9	Rifamycin use for treatment of <i>Helicobacter pylori</i> infection: a review of recent data. <i>Future Microbiology</i> , 2020, 15, 1185-1196.	2.0	7
10	Emergence of ST654 <i>Pseudomonas aeruginosa</i> co-harboring blaNDM-1 and blaGES-5 in novel class I integron In1884 from Bulgaria. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 672-673.	2.2	6
11	Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates. <i>Anaerobe</i> , 2020, 62, 102150.	2.1	5
12	ANTIMICROBIAL RESISTANCE OF BULGARIAN ISOLATES MORAXELLA CATARRHALIS DURING THE PERIOD 1999-2018. <i>Journal of IMAB</i> , 2020, 26, 3208-3212.	0.1	1
13	Multidrug resistance in <i>Helicobacter pylori</i> : current state and future directions. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 909-915.	3.1	69
14	Relation between <i>emm</i> types and virulence gene profiles among Bulgarian <i>Streptococcus pyogenes</i> clinical isolates. <i>Infectious Diseases</i> , 2019, 51, 668-675.	2.8	4
15	Multidrug resistance in anaerobes. <i>Future Microbiology</i> , 2019, 14, 1055-1064.	2.0	14
16	<i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> carriage in asymptomatic children since 2010: a narrative review. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 1228-1236.	1.3	3
17	First report of <i>Enterobacter asburiae</i> isolate, producing NDM-1 and a novel ACT-68 enzyme in Bulgaria. <i>Infectious Diseases</i> , 2019, 51, 627-629.	2.8	2
18	Quinolone resistance mechanisms among third-generation cephalosporin resistant isolates of <i>Enterobacter</i> spp. in a Bulgarian university hospital. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1445-1455.	2.7	3

#	ARTICLE	IF	CITATIONS
19	Recurrent Clostridioides (Clostridium) difficile infection in a patient suffering from inflammatory bowel disease and benefits of resistotyping. Diagnostic Microbiology and Infectious Disease, 2019, 94, 334-336.	1.8	6
20	Helicobacter pylori growth stimulation by adrenaline detected by two methods. Diagnostic Microbiology and Infectious Disease, 2019, 93, 30-32.	1.8	0
21	Multicentre investigation of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Bulgarian hospitals – Interregional spread of ST11 NDM-1-producing K. pneumoniae. Infection, Genetics and Evolution, 2019, 69, 61-67.	2.3	19
22	Molecular emm typing of Bulgarian macrolide-resistant Streptococcus pyogenes isolates. Acta Microbiologica Et Immunologica Hungarica, 2019, 67, 14-17.	0.8	6
23	MOLECULAR EPIDEMIOLOGY OF MULTIDRUG RESISTANT ENTEROBACTER CLOACAE BLOOD ISOLATES FROM A UNIVERSITY HOSPITAL. Journal of IMAB, 2019, 25, 2457-2464.	0.1	4
24	Status of Helicobacter pylori cag pathogenicity island (cag PAI) integrity and significance of its individual genes. Infection, Genetics and Evolution, 2018, 59, 167-171.	2.3	8
25	Prevalence of Helicobacter pylori is still high among symptomatic Bulgarian children. Acta Microbiologica Et Immunologica Hungarica, 2018, 66, 255-260.	0.8	4
26	ANTIBIOTIC COMBINATIONS WITH COLISTIN AGAINST CARBAPENEM-RESISTANT Klebsiella pneumoniae - in vitro ASSESSMENT. Journal of IMAB, 2018, 24, 2258-2266.	0.1	3
27	Primary Helicobacter pylori resistance in elderly patients over 20 years: A Bulgarian study. Diagnostic Microbiology and Infectious Disease, 2017, 88, 264-267.	1.8	10
28	Isolation of <i>Escherichia coli</i> ST131 producing KPC-2 in Bulgaria. Infectious Diseases, 2017, 49, 429-431.	2.8	4
29	Bacteriocin-like inhibitory activities of seven <i>Lactobacillus delbrueckii</i> subsp. <i>bulgaricus</i> strains against antibiotic susceptible and resistant <i>Helicobacter pylori</i> strains. Letters in Applied Microbiology, 2017, 65, 469-474.	2.2	38
30	Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing K. pneumoniae isolates. Diagnostic Microbiology and Infectious Disease, 2017, 89, 310-313.	1.8	12
31	Dissemination of a Multidrug-Resistant VIM-1- and CMY-99-Producing <i>Proteus mirabilis</i> Clone in Bulgaria. Microbial Drug Resistance, 2017, 23, 345-350.	2.0	8
32	Influence of Dietary Factors on <i>Helicobacter pylori</i> and CagA Seroprevalence in Bulgaria. Gastroenterology Research and Practice, 2017, 2017, 1-7.	1.5	12
33	ANTIMICROBIAL SUSCEPTIBILITY OF CLINICALLY SIGNIFICANT ISOLATES OF ENTEROBACTER SPP., OBTAINED FROM PATIENTS, HOSPITALISED IN VARNA UNIVERSITY HOSPITAL DURING THE PERIOD 2014 – 2016. Journal of IMAB, 2017, 23, 1828-1833.	0.1	0
34	Virulence arsenal of the most pathogenic species among the Gram-positive anaerobic cocci, <i>Fingoldia magna</i> . Anaerobe, 2016, 42, 145-151.	2.1	30
35	Clarithromycin Resistance Mutations in <i>Helicobacter pylori</i> in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. Microbial Drug Resistance, 2016, 22, 227-232.	2.0	27
36	Three unsuccessful treatments of Helicobacter pylori infection by a highly virulent strain with quadruple antibiotic resistance. Folia Microbiologica, 2016, 61, 307-310.	2.3	9

#	ARTICLE	IF	CITATIONS
37	<i>Helicobacter pylori</i> resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. <i>Infectious Diseases</i> , 2016, 48, 56-62.	2.8	28
38	Clonal dissemination of multilocus sequence type ST15 KPC-2-producing <i>Klebsiella pneumoniae</i> in Bulgaria. <i>Apmis</i> , 2015, 123, 887-894.	2.0	46
39	Molecular epidemiology and antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> in a Bulgarian university hospital over a 5-year period (2007-2012). <i>Infectious Diseases</i> , 2015, 47, 932-934.	2.8	1
40	Actinomycosis: a frequently forgotten disease. <i>Future Microbiology</i> , 2015, 10, 613-628.	2.0	94
41	Detection of CMY-99, a Novel Acquired AmpC-Type β -Lactamase, and VIM-1 in <i>Proteus mirabilis</i> Isolates in Bulgaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 620-621.	3.2	11
42	Predominance of IncL/M and IncF plasmid types among CTX-M-ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in Bulgarian hospitals. <i>Apmis</i> , 2014, 122, 608-615.	2.0	13
43	Serotypes, antimicrobial susceptibility, and beta-lactam resistance mechanisms of clinical <i>Haemophilus influenzae</i> isolates from Bulgaria in a pre-vaccination period. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 81-87.	1.5	8
44	First identification of KPC-2 and VIM-1 producing <i>Klebsiella pneumoniae</i> in Bulgaria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 252-253.	1.8	7
45	High Prevalence of CTX-M-15-Producing O25b-ST131 <i>Escherichia coli</i> Clone in Bulgarian Hospitals. <i>Microbial Drug Resistance</i> , 2012, 18, 390-395.	2.0	8
46	First detection of the AmpC beta-lactamase ACC-1 in a <i>Klebsiella pneumoniae</i> isolate in Bulgaria. <i>Journal of Chemotherapy</i> , 2012, 24, 307-308.	1.5	4
47	Significance of <i>Helicobacter pylori</i> vacA intermediate region genotyping—a Bulgarian study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 253-257.	1.8	19
48	<i>Helicobacter pylori</i> oipA genetic diversity and its associations with both disease and cagA, vacA s, m, and i alleles among Bulgarian patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 335-340.	1.8	37
49	Benefits of <i>Helicobacter pylori</i> cagE genotyping in addition to cagA genotyping: a Bulgarian study. <i>Antonie Van Leeuwenhoek</i> , 2011, 100, 529-535.	1.7	11
50	Detection of the sexually transmissible genital mycoplasmas by polymerase chain reaction in women. <i>Sexual Health</i> , 2011, 8, 445.	0.9	5
51	Association of iceA and babA genotypes in <i>Helicobacter pylori</i> strains with patient and strain characteristics. <i>Antonie Van Leeuwenhoek</i> , 2010, 98, 343-350.	1.7	34
52	New Variant of CTX-M-Type Extended-Spectrum β -Lactamases, CTX-M-71, with a Gly238Cys Substitution in a <i>Klebsiella pneumoniae</i> Isolate from Bulgaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4518-4521.	3.2	14
53	Nosocomial spread of OXA-23 and OXA-58 β -lactamase-producing <i>Acinetobacter baumannii</i> in a Bulgarian hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 618-620.	3.0	22
54	Antimicrobial resistance and production of beta-lactamases in Bulgarian clinical isolates <i>Moraxella catarrhalis</i> . <i>Annals of Microbiology</i> , 2009, 59, 169-172.	2.6	2

#	ARTICLE	IF	CITATIONS
55	Extended-spectrum $\hat{2}$ -lactamase-producing <i>Serratia marcescens</i> outbreak in a Bulgarian hospital. <i>Journal of Hospital Infection</i> , 2008, 70, 60-65.	2.9	39
56	Extended-Spectrum $\hat{2}$ -Lactamase-Producing Enterobacteriaceae in Bulgarian Hospitals. <i>Microbial Drug Resistance</i> , 2008, 14, 119-128.	2.0	22
57	VIM-15 and VIM-16, Two New VIM-2-Like Metallo- $\hat{2}$ -Lactamases in <i>Pseudomonas aeruginosa</i> Isolates from Bulgaria and Germany. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2977-2979.	3.2	25
58	Dissemination and persistence of a plasmid-mediated TEM-3-like $\hat{2}$ -lactamase, TEM-139, among Enterobacteriaceae in Bulgaria. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 710-714.	2.5	3
59	CTX-M-3 extended-spectrum beta-lactamase-producing <i>Klebsiella pneumoniae</i> and dissemination of the plasmidic bla CTX-M-3 in Bulgaria. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2006, 25, 123-125.	2.9	5
60	Multiresistant SHV-2- Producing <i>Salmonella enterica</i> Serotype Corvallis in Bulgaria. <i>Journal of Chemotherapy</i> , 2005, 17, 568-569.	1.5	3
61	Extended-spectrum $\hat{2}$ -lactamase (ESBL) CTX-M-15-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in Sofia, Bulgaria. <i>Clinical Microbiology and Infection</i> , 2004, 10, 752-755.	6.0	21
62	Nasopharyngeal carriage of penicillin-resistant, macrolide-resistant and multiply-resistant <i>Streptococcus pneumoniae</i> in day-care centers in Sofia, Bulgaria. <i>Clinical Microbiology and Infection</i> , 2001, 7, 42-6.	6.0	1